03.07.25 -- An Updated View of The Federal Segment: DHA Formulary Management

Live from the 2025 JP Morgan Healthcare Conference, The Business of Biotech dives into a game-changing approach to biotech financing with XOMA Royalty’s Owen Hughes & Brad Sitko. They break down their royalty aggregation model, how it mitigates risk, and why it’s an alternative to equity-based funding. Don’t miss this insightful conversation on the future of biotech capital access!

Take action to improve diversity in clinical trials by addressing underrepresentation and ensuring equitable access to medical interventions, as emphasized by the FDA’s new 2025 guidance.

What role do technology and data-driven strategies play in improving the clinical trial participant experience? Optimize how you plan for and execute the participant experience.

The Regional Site Manager (RSM) monitoring model eliminates numerous clinical trial risks by leveraging efficient, start-to-finish site management by a single, expert point of contact.

In a webinar, experts from Revvity Signals Software explored how solutions like its Spotfire platform enable better, more streamlined clinical studies.

A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.